Compare Cefiderocol to Standard Antimicrobial Therapy in Treating Nosocomial Bloodstream Infection with Gram-Negative Bacteria
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 10th, 2025
|
Hospital-acquired infections, particularly bloodstream infections, are responsible for millions of deaths each year. Mortality risk is markedly higher among patients infected with gram-negative bacteria resistant to multiple antimicrobial agents. Supported jointly by the governments of Singapore and Australia, a clinical study was conducted to evaluate the efficacy of cefiderocol, a novel antibiotic, for the treatment of nosocomial bacteremia.
The study enrolled 504 hospitalized patients with confirmed gram-negative bloodstream infections. Escherichia coli and Klebsiella pneumoniae were the most common pathogens, each accounting for approximately 30% of cases. Among Enterobacterales isolates, resistance to third-generation cephalosporins was observed in 27% of samples, and carbapenem resistance in 13%.
Participants were randomly assigned to receive either cefiderocol or standard-of-care antibiotic therapy. Cefiderocol was administered intravenously at 2 grams every 8 hours. This cephalosporin exerts its bactericidal effect by inhibiting cell wall synthesis. Its enhanced potency is thought to derive from its siderophore-like ability to exploit bacterial iron transport channels, enabling efficient penetration of the outer membrane to reach the peptidoglycan target.
Outcomes were assessed at 14, 30, and 90 days after treatment initiation. The study found no significant difference in mortality between patients treated with cefiderocol and those receiving standard antimicrobial regimens. Nevertheless, cefiderocol represents a promising therapeutic alternative for infections caused by multidrug-resistant gram-negative bacteria and may warrant further evaluation in combination with β-lactamase inhibitors.
The study enrolled 504 hospitalized patients with confirmed gram-negative bloodstream infections. Escherichia coli and Klebsiella pneumoniae were the most common pathogens, each accounting for approximately 30% of cases. Among Enterobacterales isolates, resistance to third-generation cephalosporins was observed in 27% of samples, and carbapenem resistance in 13%.
Participants were randomly assigned to receive either cefiderocol or standard-of-care antibiotic therapy. Cefiderocol was administered intravenously at 2 grams every 8 hours. This cephalosporin exerts its bactericidal effect by inhibiting cell wall synthesis. Its enhanced potency is thought to derive from its siderophore-like ability to exploit bacterial iron transport channels, enabling efficient penetration of the outer membrane to reach the peptidoglycan target.
Outcomes were assessed at 14, 30, and 90 days after treatment initiation. The study found no significant difference in mortality between patients treated with cefiderocol and those receiving standard antimicrobial regimens. Nevertheless, cefiderocol represents a promising therapeutic alternative for infections caused by multidrug-resistant gram-negative bacteria and may warrant further evaluation in combination with β-lactamase inhibitors.